PARITAPREVIR

Chronic Hepatitis C

Ain Shams UniversitySmall moleculePhase 3Dormant

A

82/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 75/ 100
Competitive Position: 95/ 100

Competitive context

3 Active assets in the Chronic Hepatitis C cohort.

Asset / Sponsor	Phase	Rating
Dasabuvir AbbVie	Phase 3	A
Ribavirin Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.	Phase 4	A
OMBITASVIR Ain Shams University	Phase 3	A
Pegylated Interferon Alpha2A Hoffmann-La Roche	Phase 4	A
Sofosbuvir Peking University First Hospital	Phase 4	A

View all 50 →

Same molecule, other indications

PARITAPREVIR is also rated in:

hepatitis C virus infectionDormant

A

Indicative ·

87 / 100

cirrhosis of liverDormant

A

Indicative ·

82 / 100

kidney failureDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.